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Introduction
Antiangiogenic therapies were conceived and developed based on 
the discovery that tumor growth relies on neovascularization (1, 2). 
These therapies are approved for treatment of a variety of human 
cancers (3) and include the monoclonal anti-VEGF antibody 
bevacizumab (4, 5) and multitargeted receptor tyrosine kinase 
inhibitors (6). However, in most clinical trials, these agents have 
only offered modest improvements in progression-free survival, 
without affecting overall survival (7). More interestingly, clinical 
trials with antiangiogenesis drugs and chemotherapy have shown 
that effects on survival coincide precisely with duration of beva-
cizumab treatment, and the progression-free survival curves tend 
to collapse or even crossover following cessation of the antiangio-
genesis drug (8–10). Therefore, concerns have been raised about a 
possible rebound in tumor growth after discontinuation of antian-
giogenic agents such as bevacizumab, and studies in patients 
with ovarian cancer are ongoing in which the effects of long-term 
versus short-term bevacizumab treatment are further evaluated 
(NCT01462890 and NCT01802749; https://clinicaltrials.gov/). 
Intriguingly, rapid vascular regrowth (11, 12) and an increase of 
Ki67 and tumor grade (13) were seen in patients after withdrawal 
of antiangiogenic agents. Additionally, preclinical models sug-
gest that antiangiogenic therapy inhibited primary tumor growth 
but resulted in increased metastatic potential of tumors through 
poorly understood mechanisms (14–16).
Our experimental findings implicate a prominent role for 
platelet extravasation in the rebound tumor growth following ces-
sation of antiangiogenesis therapy. The clinical observation that 
thrombocytosis is frequently associated with cancer was made 
more than 100 years ago (17, 18). Recent studies indicate that 
platelets are integral elements of the tumor microenvironment; 
platelets were shown to be crucial for tumor growth (19), chemore-
sistance (20), and metastasis (21, 22). Additionally, patients with 
ovarian cancer with an increased number of platelets at the time of 
initial diagnosis have significantly worse overall and progression-
free survival (20, 23). We recently discovered a novel mechanism 
whereby paraneoplastic thrombocytosis is a result of a paracrine 
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Increased platelet infiltration into tumors after withdrawal of 
antiangiogenic therapy. We and others have shown that platelets 
enhance tumor growth (19, 23, 26), chemoresistance (20), and 
metastasis (21, 22). Although platelet number and function can be 
altered by hypoxia (27–29), the functional effects of hypoxia in the 
tumor microenvironment on platelets are unknown. Therefore, we 
examined whether platelet infiltration into the tumor microenvi-
ronment could contribute to tumor growth following cessation of 
antiangiogenic therapy. Withdrawal of bevacizumab treatment led 
to a 3.5-fold increase in platelet infiltration compared with that after 
control or long-term bevacizumab treatment (Figure 2, A and B). 
Platelets attached to endothelial cells and extravasated in between 
endothelial cells into the tumor microenvironment (Supplemental 
Figure 2, A and B). Given the role of ADP as a potent platelet agonist 
(30, 31) and the hypoxia resulting from antiangiogenic drugs, we 
investigated the effect of hypoxia on ADP secretion by cancer cells. 
SKOV3ip1 ovarian cancer cells grown in a hypoxic environment 
(1% oxygen) for 24, 48, and 72 hours produced 2-fold, 4.3-fold, and 
5.6-fold more ADP than cells grown under normoxia (21% oxygen), 
respectively, as was determined by measuring ADP concentration 
in serum-free cell culture media incubated with cancer cells (Fig-
ure 2C). Likewise, in vivo tumors resected from mice exposed to 
bevacizumab for 7 days had significantly higher ADP concentra-
tions than either the untreated controls or tumors continuously 
treated with bevacizumab (Figure 2D). To further assess how plate-
lets regulate tumor cell characteristics, various ovarian cancer cells 
were exposed to platelets. Coincubation significantly increased 
tumor cell proliferation (Figure 2E), which was dependent on plate-
let activation (Figure 2F). Activation of platelets by tumor cells was 
demonstrated by surface expression of P-selectin (also known as 
CD62P) and the active form of CD41/CD61 (also known as GpIIb/
IIIa complex). These results showed that 23% (±8.5%) of platelets 
were positive for P-selectin and 37% (±15.5%) were positive for the 
GpIIb/IIIa complex after coincubation with tumor cells (Supple-
mental Figure 2C). These findings are supported by a prior report 
(32). Additionally, platelets also significantly decreased apoptosis 
(Supplemental Figure 2D) and increased tumor cell invasion (Sup-
plemental Figure 2E).
Platelets are decisive for tumor outgrowth after withdrawal of 
antiangiogenic therapy. Next, we examined the effect of platelet 
counts on tumor growth and the response to antiangiogenic ther-
apy. To alter platelet counts, we induced thrombocytosis by trans-
fusion of platelets and thrombocytopenia by i.v. injection of the 
monoclonal anti-glycoprotein Ibα (GPIbα) antibody twice weekly, 
respectively. Mice carrying A2780ip2 tumors were randomized to 
the following groups: untreated control, platelet transfused, and 
platelet depleted by antiplatelet antibody (APA). Platelet counts 
were measured at the time of necropsy (Supplemental Figure 3A). 
Mice receiving platelet transfusions twice weekly had on average 
1.9- and 5.4-fold higher tumor weight compared with the control 
group and with mice treated with APA twice weekly, respectively 
(Figure 3A). Similar results were obtained in the SKOV3ip1 model 
(Supplemental Figure 3B). Tumors resected from platelet-trans-
fused mice showed significantly higher proliferation (Figure 3B) 
and a lower apoptosis rate (Figure 3C) compared with those of con-
trol mice, as measured by the number of Ki67+ tumor cell nuclei and 
the number of cleaved caspase-3–positive tumor cells, respectively. 
circuit of thrombopoietic cytokines in tumor and host tissue (23). 
We found that platelets extravasate from the tumor microvascu-
lature into the tumor microenvironment (23), in which they can 
release cytokines with angiogenic and mitogenic roles and serve 
as important regulators of angiogenesis (24, 25). We believe that 
our findings demonstrate a pivotal role for platelets in stimulating 
rebound tumor growth and identify novel therapeutic opportuni-
ties to block such effects.
Results
Withdrawal of antiangiogenic therapy results in accelerated tumor 
growth. To determine the impact of withdrawal of different 
antiangiogenic agents compared with continuous treatment in 
orthotopic mouse models of ovarian cancer, we carried out a 
set of experiments in which we injected mice i.p. with various 
human or mouse ovarian cancer cells (day 0). These mice were 
randomized into three groups: control; withdrawal of antiangio-
genic therapy (treatment from day 7–14); and continuous antian-
giogenic therapy (treatment from day 7 until necropsy) (Figure 
1A). Withdrawal of treatment with pazopanib (a multitargeted 
receptor tyrosine kinase inhibitor) in mice bearing SKOV3ip1 
tumors resulted in a significant increase in tumor growth as 
compared with that in the control group, whereas continuous 
pazopanib treatment significantly reduced the aggregate tumor 
weight as well as the number of tumor nodules (Figure 1, B and 
C). We observed similar results using different ovarian cancer 
models and different antiangiogenic agents: pazopanib in HeyA8 
tumors (Supplemental Figure 1, A and B; supplemental material 
available online with this article; doi:10.1172/JCI85086DS1) and 
bevacizumab (a humanized monoclonal anti-VEGF antibody) in 
the 2774 tumors (Figure 1D and Supplemental Figure 1, C and D). 
After withdrawal of antiangiogenic therapy, i.p. tumor nodules 
induced by the 2774 ovarian cancer cells exhibited increased 
areas of hypoxia, as detected by staining for pimonidazole adduct 
formation (Figure 1, E and G), and increased vascular leakage, as 
determined by extravascular FITC-dextran (Figure 1, F and H). 
Moreover, analysis of CD31+ microvessels (Figure 1, I and J) and 
desmin+ pericytes covering endothelial cells (Figure 1, I and K) 
showed increased microvessel density but reduced pericyte cov-
erage after withdrawal of the antiangiogenic drug.
Figure 1. Tumor rebound after cessation of antiangiogenic therapy. 
(A) Therapeutic schema for withdrawal and continuous treatment with 
antiangiogenic therapy. (B) Mean aggregate tumor weight and (C) number 
of nodules of tumors induced by i.p. injection of SKOV3ip1 human ovarian 
cancer cells into nude mice with various antiangiogenic treatment sched-
ules. (D) Mean aggregate tumor weight of 2774 ovarian tumors after bev-
acizumab withdrawal or continuous treatment. (E) Visualization of tumor 
hypoxia and (F) vascular permeability after i.v. injection of hypoxyprobe 
and dextran, respectively. Scale bar: 100 μm. (G and H) The quantification 
of hypoxyprobe staining and the number of FITC+ dextran pixels after indi-
cated treatments. (I–K) Vessel number and pericyte coverage after antian-
giogenic therapy withdrawal and continuous treatment. (I) Representative 
immunofluorescence staining and (J and K) bar graphs. HPF, high-powered 
field. Scale bar: 100 μm. (B–D) n = 8–10 mice per group. (E, F, and I) Rep-
resentative images from at least 5 mice per group. *P < 0.05, **P < 0.01, 
***P < 0.001 (1-way ANOVA followed by a Tukey’s multiple comparison 
post-hoc test in B–D, G, H, J, and K). Averaged data are presented as the 
mean ± SEM. Paz, pazopanib; Bev, bevacizumab.
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therapy (Figure 3, D and E). To further investigate our hypothesis 
that platelets are crucial for the rebound of tumor growth after with-
drawal of antiangiogenic therapy, we performed an additional in 
vivo experiment. Mice were injected with A2780ip2 ovarian cancer 
cells and randomized into three groups: control IgG; APA alone; and 
APA plus bevacizumab withdrawal. APA treatment was started on 
the day of tumor cell injection and was continued until the end of 
the experiment. In the withdrawal group, treatment with bevaci-
zumab was started 1 week after tumor cell injection and withdrawn 
after a week of treatment. Supplemental Figure 3E shows that tumor 
weight was reduced by 82% in the group that received APA alone 
and by 67% in the group that received APA plus bevacizumab with-
drawal. Although tumor weight was slightly higher in the group that 
received APA plus bevacizumab withdrawal, there was no signifi-
cant difference compared with the group that received APA alone. 
These results highlight platelets as important mediators of tumor 
progression after cessation of antiangiogenic therapy. Platelets are 
known to store and secrete various tumorigenic and angiogenic pro-
teins (24) that can promote tumor growth. To determine whether 
the quantity of angiogenic proteins changes in the withdrawal set-
ting, we treated mice with A2780ip2 i.p. tumors with bevacizumab 
To determine whether transfused platelets were infiltrating into 
tumors, mice with SKOV3ip1 tumors were injected with 300 × 106 
platelets from Pf4-Cre–yellow fluorescence protein (Pf4-Cre-YFP) 
mice, which allowed for specific labeling of the megakaryocytic 
lineage, including platelets with YFP (23). Representative immun-
ofluorescence images showed that i.v.-infused platelets were pres-
ent in tumor tissues (Supplemental Figure 3C). Moreover, direct 
and indirect coculture of HeyA8 ovarian cancer cells with platelets 
showed that HeyA8 cells directly interacting with either intact or 
lysed platelets substantially increased their proliferation rate. How-
ever, the proliferation rate of cancer cells that were separated from 
platelets by a dense endothelial monolayer was almost equal to that 
of control cells that were not exposed to platelets (Supplemental 
Figure 3D). To investigate the relationship between platelet counts 
and accelerated tumor growth after withdrawal of antiangiogenic 
therapy, tumor-bearing nude mice were subjected to withdrawal 
of antiangiogenic therapy in combination with APA for platelet 
depletion. Lowering platelet counts completely abolished rebound 
in tumor growth after antiangiogenic withdrawal in both A2780ip2 
and HeyA8 tumor models and maintained the tumor weight at the 
same level as that in mice receiving continuous antiangiogenic 
Figure 2. Antiangiogenic treatment, hypoxia, and platelet effect on cancer cells. (A) The number of extravasated platelets in 2774 ovarian cancer cell–
induced tumors in control mice and mice exposed to bevacizumab withdrawal or long-term treatment. (B) Representative immunofluorescence staining 
of tumors resected from control mice and mice exposed to bevacizumab withdrawal and long-term bevacizumab treatment. CD31 (red) is an endothelial 
marker, and GPIbβ (green) is a platelet marker. Scale bar: 100 μm. (C) ADP concentrations (μM) in supernatants of SKOV3ip1 cells grown in hypoxia (1% 
oxygen) or normoxia (21% oxygen) for 24, 48, and 72 hours (n = 3). (D) ADP levels (μM) in SKOV3ip1 tumors resected from mice exposed to long-term bev-
acizumab or withdrawal of bevacizumab. (E) Increase in proliferation of different ovarian cancer cell lines after exposure to platelets for 72 hours, as mea-
sured by EdU incorporation (n = 3). (F) Proliferation of HeyA8 ovarian cancer cells after coincubation with normal or 1% paraformaldehyde-fixed platelets  
(n = 3). (A and B) Quantification and representative images from tumors of at least 5 mice per group. (D) Quantification of ADP levels in tumors of 2 mice 
per group. *P < 0.05, **P < 0.01, ***P < 0.001 (1-way ANOVA followed by a Tukey’s multiple comparison post-hoc test in A, D, and F; 2-tailed Student’s t 
test in E). Averaged data are presented as the mean ± SEM.
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of FAK in the murine host on the rebound growth of the inocu-
lated tumors after antiangiogenic withdrawal, we inhibited FAK 
expression in nude mice carrying HeyA8 human ovarian can-
cer cell–induced tumors using a mouse-specific anti-FAK siRNA 
incorporated in chitosan nanoparticles. Mouse anti-FAK siRNA 
chitosan nanoparticles reduced expression of FAK in the murine 
host (including host megakaryocytes and platelets) but did not 
affect FAK levels in human ovarian cancer cells (Supplemental 
Figure 4A). Moreover, proliferation and apoptosis of HeyA8 cells 
was not changed upon transfection with the mouse-specific FAK 
siRNA (Supplemental Figure 4, B and C). Reducing FAK expres-
sion in the host decreased tumor weight by 69% (Supplemental 
Figure 4D) and the number of tumor nodules by 56% (Supple-
mental Figure 4E) and abrogated tumor growth rebound after 
withdrawal of antiangiogenic therapy. To further study the effect 
of platelet FAK, we used platelet-specific FAK-deficient mice 
for the length of the entire experiment or for 7 days with subsequent 
withdrawal. Platelet proteins were isolated from each group at the 
end of the experiment. Evaluation of 53 angiogenesis-related pro-
teins in platelets revealed that the quantity of the analyzed proteins 
was not significantly different between the two groups (Supplemen-
tal Figure 3F). Therefore, it is likely to be the number of platelets 
infiltrating into the tumor microenvironment and directly interact-
ing with cancer cells, and not the quantity of angiogenic proteins, 
that is the crucial factor for tumor rebound growth after withdrawal 
of antiangiogenic drugs.
Platelet expression of focal adhesion kinase is crucial for platelet 
migration. An important regulator of shape change and move-
ment of platelets is focal adhesion kinase (FAK, also known as 
protein tyrosine kinase 2 [PTK2]) (33). FAK is overexpressed in 
a variety of human cancers (34) and is at the interface of tumor 
cells and their microenvironment (35). To investigate the effect 
Figure 3. Platelets are important mediators of tumor rebound growth after withdrawal of antiangiogenic therapy. (A) Mean aggregate tumor weight of 
A2780 cell–induced tumors in mice receiving platelet transfusions or APA twice weekly. (B and C) Representative immunohistochemical staining for (B) 
Ki67 and (C) caspase-3 and their quantification in control tumors (black bars) and tumors transfused with platelets (gray bars) twice weekly. Scale bar: 
50 μm. (D and E) Mean aggregate tumor weight in (D) A2780 cell– or (E) HeyA8 cell–induced i.p. tumors for each indicated treatment group. (A, D, and E) 
n = 8–10 mice per group. (B and C) Representative images from tumors of at least 5 mice per group. **P < 0.01, ***P < 0.001 (1-way ANOVA followed by a 
Tukey’s multiple comparison post-hoc test in A, D, and E; 2-tailed Student’s t test in B and C). Averaged data are presented as the mean ± SEM.
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Figure 4. Role of platelet FAK on tumor growth. (A) Mean aggregate tumor weight and (B) representative images of necropsy in WT or platelet-specific 
FAK-deficient mice that carried tumors induced by i.p. injection of ID8-VEGF murine ovarian cancer cells and were exposed to long-term treatment or 
withdrawal of anti-VEGF antibody (B20). (C) Quantification of extravasated platelets in ID8-VEGF tumors in WT or platelet-specific FAK-deficient mice. 
(D) Mean aggregate tumor weight and (E) number of tumor nodules of orthotopic SKOV3ip1 tumors after treatment with pazopanib, the FAK inhibitor 
GSK2256098 (FAKi), or a combination of the two. (F) Mean aggregate weight of orthotopic SKOV3ip1 tumors after withdrawal or long-term antiangiogenic 
therapy alone or in combination with FAK inhibitor GSK2256098. (A and D–F) n = 8–10 mice per group. (B and C) Quantification and representative images 
of tumors from at least 5 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001 (1-way ANOVA followed by a Tukey’s multiple comparison post-hoc test in A 
and C–F). Averaged data are presented as the mean ± SEM.
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(Pf4-Cre Fakfl/fl mice; ref. 33) in our antiangiogenic therapy with-
drawal model. We confirmed the absence of FAK protein in plate-
lets isolated from these mice. Furthermore, we isolated CD19+ B 
cells, CD3+ T cells, and F4/80+ macrophages from the spleens of 
Pf4-Cre Fakfl/fl mice using a cell sorter and extracted their RNA. 
qRT-PCR analysis did not show any significant change in the 
expression of Fak mRNA in white blood cells of Pf4-Cre Fakfl/fl 
mice (Supplemental Figure 5A). Intriguingly, platelet-specific FAK 
deficiency prevented a rebound in tumor growth after withdrawal 
of the anti-VEGF antibody (B20), as was demonstrated by a sig-
nificant reduction in tumor weight (Figure 4A) and number of 
tumor nodules (Supplemental Figure 5B). Figure 4B shows repre-
sentative images of WT and platelet-specific FAK-deficient mice 
at the time of necropsy. In addition, immunofluorescence staining 
of resected tumors showed a reduction in platelet infiltration into 
the tumor microenvironment in platelet-specific FAK-deficient 
mice as compared with control mice (Figure 4C and Supplemental 
Figure 5C). Most notably, we did not detect any increase in plate-
let infiltration after withdrawal of antiangiogenic therapy in mice 
with platelet-specific FAK deficiency. Loss of FAK in platelets did 
not affect the platelet blood counts in the peripheral blood of these 
mice (Supplemental Figure 5D). Furthermore, ID8-VEGF murine 
ovarian cancer cells cocultured with WT platelets showed slightly 
increased proliferation compared with cells exposed to Fak–/– 
platelets (Supplemental Figure 5E); however, these effects were 
minimal. Rates of apoptosis were not different between WT and 
Fak–/– platelets (Supplemental Figure 5F). These results highlight 
the fact that the diminished platelet infiltration upon loss of FAK 
is likely to be the main factor responsible for the rebound in tumor 
growth after withdrawal of the antiangiogenic therapy.
FAK inhibitors can block tumor rebound after cessation of antian-
giogenic therapy. To further investigate the role of FAK on tumor 
response to antiangiogenic agents, we used a small-molecule 
inhibitor that targets FAK phosphorylation in orthotopic mouse 
models of ovarian and uterine cancer (34, 35). GSK2256098 is a 
reversible, highly selective small-molecule inhibitor that targets 
FAK activity and Y397 phosphorylation (36, 37). We assessed the 
effectiveness of GSK2256098 by measuring FAKY397 phosphory-
lation in SKOV3ip1 and HeyA8 cells in vitro (Supplemental Fig-
ure 6, A and B). To determine the in vivo effects of GSK2256098, 
we treated mice carrying SKOV3ip1 tumors with pazopanib, 
GSK2256098, or a combination of both. Combination of pazo-
panib and GSK2256098 resulted in a significant reduction in 
tumor weight (Figure 4D) and the number of tumor nodules (Fig-
ure 4E) as compared with those in the single-treatment groups. 
Moreover, FAK inhibition reduced platelet infiltration into the 
tumor (Supplemental Figure 6C). Similar results were obtained 
with HeyA8 ovarian cancer cells (Supplemental Figure 6, D and E), 
although the effect was less pronounced than that in the SKOV3ip1 
tumors, probably because of the smaller effect of GSK2256098 on 
FAKY397 phosphorylation in these cells. Considering that inhibition 
of FAK had substantial antitumor effects in combination with an 
antiangiogenic agent, we investigated whether inhibition of FAK 
abrogates the rebound in tumor growth after withdrawal of antian-
giogenic therapy. Therefore, we performed an experiment in which 
we administered GSK2256098 after withdrawal of bevacizumab. 
We found that GSK2256098 treatment of mice completely blocked 
acceleration in tumor growth after withdrawal of pazopanib or bev-
acizumab in both SKOV3ip1- (Figure 4F and Supplemental Figure 
7A) and HeyA8-induced tumors (Supplemental Figure 7, B and C).
Discussion
In the current study, we have modeled tumor rebound after with-
drawal of a variety of antiangiogenic agents. Tumor outgrowth after 
cessation of treatment was associated with increased intratumoral 
hypoxia, tumor angiogenesis, vascular permeability, and platelet 
Figure 5. Proposed model of the interactions 
among antiangiogenic therapy, platelets, and FAK 
and their effect on tumor growth. Withdrawal of 
antiangiogenic therapy leads to tumor hypoxia, ADP 
production, increased angiogenesis, and platelet 
infiltration, thereby increasing tumor growth. On 
the other hand, continuous antiangiogenic therapy 
and/or FAK inhibitors might be a potential regimen 
to prevent tumor rebound after cessation of antian-
giogenic therapy.
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gested that the number of platelets rather than their quantitative 
protein content is important for tumor rebound after withdrawal 
of antiangiogenic therapy. Altogether, this implies that reducing 
platelet levels in the blood can be a potent antiproliferative and 
antimetastatic strategy (19, 21). Indeed, our results indicated that, 
regardless of the time of administration of APA, reducing plate-
let counts significantly inhibited tumor rebound after withdrawal 
of bevacizumab. However, lowering platelet numbers in patients 
with cancer requires careful titration, as thrombocytopenia can 
easily lead to life-threatening bleeding complications. Although 
platelet function and numbers can change under hypoxic con-
ditions (27–29, 55), their role in tumor hypoxia, especially with 
regard to antiangiogenic therapy–induced hypoxia, is not well 
understood. We showed that increased platelet infiltration after 
withdrawal of antiangiogenic therapy was dependent on expres-
sion of FAK in platelets. Intriguingly, platelet-specific knockout 
of FAK completely blocked tumor outgrowth after cessation of 
antiangiogenic therapy. Although tumor weight was not signifi-
cantly different between the two control groups, platelet infiltra-
tion was significantly reduced in tumors of Pf4-Cre+ Fakfl/fl mice. 
One explanation could be that platelets extravasated even before 
a detectable increase in tumor growth. This is supported in a 
recent publication by Qi et al. (56), who showed that, in human 
colorectal adenomas, platelet infiltration can be detected even 
before the presence of adenocarcinoma; however, the number of 
infiltrating platelets increased further during carcinoma devel-
opment. Another possible explanation as to why tumor weights 
were not significantly different is that the time point of necropsy 
was dependent on the group of WT mice in which antiangiogenic 
therapy was withdrawn; these mice became moribund much ear-
lier than the Pf4-Cre+ Fakfl/fl mice. The Pf4-Cre+ Fakfl/fl system was 
published and characterized earlier (33). The authors evaluated 
the expression of FAK in megakaryocytes and platelets as well 
as in several other organs. FAK was absent only in megakary-
ocytes and platelets. However, recent work by Pertuy et al. (57) 
showed that the Pf4-Cre transgene might have a broader expres-
sion beyond the megakaryocytic lineage. Pertuy et al. found 
that 0.3% of CD45+ leukocytes as well as a small percentage 
of intestinal epithelial cells showed expression of Pf4. Despite 
these results, the authors confirmed that the Pf4-Cre system is 
extremely valuable and a powerful instrument to study the func-
tion of megakaryocytes and platelets in diverse physiological and 
pathological settings, as also shown by others (58). We confirmed 
the absence of FAK protein in platelets of Pf4-Cre+ Fakfl/fl mice. 
Moreover, Fak mRNA expression was not significantly different 
in various immune cells isolated from the spleens of WT and Pf4-
Cre+ Fakfl/fl mice.
Comparable results with regard to tumor growth and tumor 
rebound after withdrawal of antiangiogenic therapy were found 
using the FAK inhibitor GSK2256098, which combined well when 
given together with the antiangiogenic agents pazopanib or beva-
cizumab. GSK2256098 is a highly specific small-molecule inhib-
itor for FAK, both for humans and mice, and has been designed 
to block FAKY397 phosphorylation which is necessary for kinase 
activation (59). Experimental evidence highlights FAK as an 
important player on multiple levels during the metastatic cascade, 
including the regulation of tumor cell motility and invasion as well 
infiltration (Figure 5) as compared with continuous antiangiogenic 
therapy. Platelet infiltration was dependent on FAK expression, 
and inhibition of FAK in the platelets itself or by a FAK inhibitor 
prevented tumor outgrowth after cessation of therapy.
Antiangiogenic agents are used for various human cancers 
(3). Recently, the human monoclonal anti-VEGF antibody beva-
cizumab was approved by the FDA for platinum-resistant recur-
rent ovarian cancer based on a phase III clinical study comparing 
bevacizumab plus chemotherapy to chemotherapy alone (38–40). 
However, the effect on progression-free survival was modest. 
Moreover, studies completed in patients with ovarian cancer in 
which bevacizumab was given in combination with chemother-
apy over either a short time or until disease progression show that 
shortly after bevacizumab withdrawal survival curves collapse 
(8–10). These findings are quite distinct from those of prior phase 
III clinical trials with chemotherapy alone in which progression-
free survival curves consistently remain separate (41, 42). These 
results suggested that, especially in high-risk patients, it might 
be beneficial to further extend the treatment duration of bevaci-
zumab beyond chemotherapy and even after disease progression. 
Therefore, ongoing trials (NCT01462890 and NCT01802749; 
https://clinicaltrials.gov/) are addressing these important ques-
tions in ovarian cancer, whereas studies in colorectal and breast 
cancer already provided evidence of benefit (43, 44).
Preclinical studies have shown that antiangiogenic agents 
induce pronounced hypoxia and in turn might facilitate metasta-
sis (45). However, whether tumor regrowth occurs after discon-
tinuation of antiangiogenic therapy is controversial. Results from 
a study using various different cell lines indicate that tumors that 
relapsed after cessation of therapy did not grow faster compared 
with untreated tumors (46). However, most of this work was done 
by injecting cancer cells subcutaneously where tumor-related 
angiogenesis is highly different from that at orthotopic sites (47). 
Hypoxic tumors have abnormal and highly heterogeneous blood 
vessels, with disorganized endothelial cells and a lack of pericytes 
(48, 49). Concordant with these findings, we found increased 
tumor angiogenesis associated with intratumoral hypoxia and 
vascular leakage after withdrawal of antiangiogenic therapy. 
This might be counterintuitive, as one would expect that more 
vessels would theoretically lead to reduced hypoxia. However, 
our results are supported by those of earlier studies, in which 
short-term treatment with an anti-VEGFR2 antibody indeed 
increased hypoxia and HIF-1α expression in the tumor, which in 
turn increased tumor angiogenesis (50–52). Increased vascular 
permeability can lead to platelet infiltration to a great extent (23). 
Once in the tumor, platelets can secrete a wide variety of prosur-
vival and proangiogenic cytokines (24). Therefore, it is not sur-
prising that they are crucial for tumor cell survival. Indeed, nearly 
40% of people with platelet counts over 400,000 per cubic mil-
limeter without any evidence of iron deficiency or inflammatory 
conditions have an occult cancer, most commonly ovarian cancer, 
among others (53). Aside from the clinic, experimental evidence 
suggests that platelets can drive tumor progression and metasta-
sis via various mechanisms (54). Our own experiments indicated 
that platelets transfused into mice indeed homed to the tumor 
tissue and that direct contact of tumor cells with platelets is cru-
cial for tumor cell proliferation. Furthermore, these results sug-
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platelet-rich plasma fraction was passed through a filtration column 
of Sepharose 2B beads (Sigma-Aldrich) loaded into a siliconized glass 
column with a 10-μm nylon net filter (Millipore). Sepharose 2B beads 
were previously washed in acetone 1:1 (vol/vol), followed by PBS 1:1 
(vol/vol) twice. Cloudy eluents, which contained platelets, were col-
lected. Platelets were counted with a hemocytometer by phase-con-
trast microscopy at ×400 magnification and immediately used for 
subsequent experiments. For protein expression analysis, platelets 
were washed once with PBS and lysed in RIPA buffer containing phos-
phatase and protease inhibitors.
In vivo experiments. In all the experiments, orthotopic models of 
ovarian cancer were used as described previously (61). Nude mice 
were injected with the indicated numbers of human ovarian cancer 
cells, whereas immunocompetent C57BL/6J WT and Pf4-Cre+ Fakfl/fl 
mice were injected with the murine ovarian cancer cell line ID8-
VEGF. For all i.p. cell injections, cells were harvested at 70% to 80% 
confluence using trypsin-EDTA, neutralized with FBS-containing 
media, washed, and resuspended to the appropriate cell number in 
Hanks’ balanced salt solution (Gibco) before injection. For SKOV3ip1, 
A2780, and ID8-VEGF i.p. tumors, 1 × 106 cells in a total volume of 
200 μl were injected; for HeyA8 tumors, 250 × 103 cells in a total vol-
ume of 200 μl were injected; and for 2774 tumors, 2 × 106 cells in a 
total volume of 200 μl were injected. For all therapeutic experiments, 
10 mice per group were used. Unless indicated otherwise, treatments 
with pazopanib (100 mg/kg p.o. daily, GlaxoSmithKline) or bevaci-
zumab (6.25 mg/kg i.p. twice weekly, Genentech) were started 1 week 
after cell injection and either withdrawn after 1 week or continued for 
approximately 4 weeks until necropsy. 0.5% hydroxypropylmethyl 
cellulose/0.1% Tween-80 and PBS were used as a vehicle control for 
all pazopanib and bevacizumab/B20 experiments, respectively. In 
selected experiments, mice were pretreated with pazopanib daily for 
7 days prior to cell inoculation to exclude that any preconditioning of 
the tumor microenvironment by the drug prior to cell injection was 
responsible for tumor rebound after withdrawal. Platelet transfusions 
were done twice weekly, and the respective animals received 6 × 108 
platelets i.v. For YFP-labeled platelets, platelets were isolated from 
transgenic C57BL/6 mice expressing YFP under the control of the Pf4 
platelet–specific promoter, and 300 × 106 platelets were transfused 
into tumor-bearing mice. Mice were anesthetized and perfused with 
4% paraformaldehyde. Microscopy for YFP-labeled platelets was 
performed using a bandpass emission filter for a peak wavelength of 
519 nm, given that the emission peak of YFP is 527 nm. To deplete 
platelets in mice, indicated animals received a rat anti-mouse mono-
clonal antibody directed against mouse GPIbα (R300; Emfret Ana-
lytics) twice weekly that caused irreversible Fc-independent platelet 
depletion within 60 minutes of administration, without inducing 
platelet activation. A polyclonal nonimmune rat IgG antibody was 
used as the vehicle control (C301; Emfret Analytics). FAK inhibi-
tor (GSK2256098) was administered daily (75 mg/kg, p.o.) in 10% 
1-methyl-2-pyrrolidinone in polyethylene glycol 300 as a carrier for 
the indicated experiments. The carrier alone was used as a vehicle 
control. In selected experiments GSK2256098 was given after with-
drawal bevacizumab or pazopanib. For all experiments, once mice in 
any group became moribund they were sacrificed, and their tumors 
were harvested. Tumor weight and the number of tumor nodules were 
recorded. Tumor tissue was fixed in formalin for paraffin embedding, 
frozen in optimal cutting temperature media to prepare frozen slides, 
as tumor angiogenesis (60). Hence, as earlier work suggested, tar-
geting FAK with a small-molecule inhibitor might be beneficial 
for overcoming adaptive mechanisms following antiangiogenic 
therapy. Indeed, our in vivo experiments suggested that inhibiting 
FAK significantly reduced infiltration of platelets and prevented 
subsequent tumor growth. This has not been shown previously to 
our knowledge, and, although the small-molecule inhibition used 
in this study affects both mouse and human cells (34, 35), inhibi-
tion of platelet infiltration represents an additional mode of action 
that leads to a reduction in tumor growth.
Overall, our findings have important clinical implications 
in patients treated with antiangiogenic therapies and provide a 
mechanism for accelerated tumor growth after cessation of ther-
apy. Our data demonstrate a role for platelet accumulation in the 
tumor microenvironment following treatment with and with-
drawal of antiangiogenic agents and identify FAK inhibitors as 
a potential regimen to prevent tumor rebound after cessation of 
antiangiogenic therapy.
Methods
Reagents. Pazopanib and the FAK inhibitor GSK2256098 were 
obtained from GlaxoSmithKline under material transfer agreement. 
Bevacizumab (Avastin) was obtained from Roche and B20 was 
obtained from Genentech.
Cell lines and siRNA transfections. All cell lines used in this study 
were obtained from the institutional Cell Line Core laboratory, and, 
per institutional policy (MD Anderson Cancer Center policy ACA 
1044), cell line authentication was performed every year. Addition-
ally, cell lines were routinely tested for mycoplasma contamination 
using the MycoAlert Kit (Lonza). Human ovarian cancer cell lines 
HeyA8, SKOV3ip1, OVCAR5, and A2780 were cultured in RPMI-1640 
(Sigma-Aldrich) supplemented with 10% to 15% FBS and 0.1% gen-
tamicin sulfate (GeminiBioproducts); murine ovarian cancer cell lines 
ID8 and ID8-VEGF were grown in DMEM medium supplemented 
with 5% FBS and 1% Insulin-Transferrin-Sodium Selenite (Roche); 
and the human ovarian cancer cell line 2774 was maintained in MEM 
medium supplemented with 5% FBS, 1× sodium pyruvate (100 mM 
stock, Invitrogen), and 1× nonessential amino acid (Gibco). Cells 
were maintained at 37°C in a humidified incubator infused with 20% 
O2 and 5% CO2. For hypoxia experiments, cells were incubated in an 
oxygen-controlled hypoxia chamber at 1% O2. All siRNA transfections 
were done using RNAiMAX reagent (Invitrogen) using forward trans-
fection protocol, and media were changed after 6 hours.
Mice. Female athymic nude mice were purchased from Taconic 
Farms, and platelet-specific FAK-deficient mice (Pf4-Cre+ Fakfl/fl mice) 
were a gift from Ian Hitchcock (Stony Brook Medicine, New York, New 
York, USA) (33). Mice were cared for according to guidelines set forth 
by the American Association for Accreditation of Laboratory Animal 
Care and the US Public Health Service policy on Human Care and Use 
of Laboratory Animals. All animals used were 8 to 12 weeks old at the 
time of cell injection.
Mouse platelet isolation. Platelets were prepared in a manner that 
would remove plasma contents and nucleated cells. Whole blood was 
drawn from the inferior vena cava of anesthetized nude mice into a 
syringe preloaded with 1:9 (vol/vol) 3.8% sodium citrate and mixed 1:1 
(vol/vol) with Tyrodes buffer lacking Mg2+ and Ca2+. Blood was cen-
trifuged at 1,100 rpm (200 g) for 6 minutes at room temperature. The 
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approximately 24 hours prior to the start of treatment. Platelets were 
isolated (as described above), and 20 × 106 platelets were added to 
the cells. After 48 hours (for proliferation) and 72 hours (for apopto-
sis), the number of proliferating cells was analyzed using the Click-
iT EdU Flow Cytometry Kit (Invitrogen) according to the manufac-
turer’s instructions. Apoptosis and cell viability were assessed using 
Annexin V and 7-amino-actinomycin-D staining (BD Pharmingen), 
respectively. For indirect coculture of HeyA8 cells and platelets sep-
arated by an endothelial monolayer, 1 × 104 HeyA8 cells were seeded 
in 24-well plates. At the same time, 1 × 105 human immortalized blood 
endothelial cells (a gift of Dontscho Kerjaschki, Medical University 
Vienna, Vienna, Austria) were seeded on a Transwell insert (catalog 
PIHT12R48, Millipore) after being coating with 20 μg/ml fibronectin 
(catalog F1141, Sigma-Aldrich). Complete confluency of the endothe-
lial monolayer was checked before pursuing the experiment. The next 
day HeyA8 cells were starved overnight, and 10 × 106 platelets were 
added. The proliferation assay was performed as described above. 
Experiments were performed 3 times in duplicates.
In vitro invasion. To assess the effect of platelets on cancer cell 
invasion, a modified Boyden chamber system was used. The wells 
were separated by a 0.1% gelatin-coated, cell-permeable membrane. 
Platelets were isolated and added to a final concentration of 1 × 108 to 
the lower chamber. Cancer cells (105 cells per well) were added to the 
upper chamber and incubated overnight at 37°C. After incubation, the 
cells in the upper chamber were removed with cotton swabs. Cells on 
membrane were fixed, stained, and counted using light microscopy. 
Cells from 5 random fields were counted. Experiments were done in 
duplicate and performed 3 times.
Assessing surface marker expression in platelets after tumor cell 
coincubation. Platelets were isolated as described above, and approx-
imately 200 × 106 platelets were added to 3 × 105 HeyA8 cells in a 
low-attachment plate (catalog 3471, Corning) for 2 hours. Thereaf-
ter, cell-platelet mixture was collected, washed once with PBS, and 
resuspended in 50 μl of Tyrodes buffer. 5 μl of anti–GPIbβ Dylight 
488 (catalog X488, Emfret) and 5 μl of anti-CD62P-PE (catalog 
M130-2, clone Wug.E9, Emfret) or anti-CD41/CD61-PE (active 
form, catalog M023-2, clone JON/A, Emfret) was added and incu-
bated for 15 minutes in the dark. Thereafter, 400 μl of PBS was 
added to stop the staining reaction. As a positive control, platelets 
were incubated with 0.5 U/ml of human thrombin (catalog T6884, 
Sigma-Aldrich) and immunostained accordingly. FACS analysis was 
done on a Beckman Coulter Gallios Flow Cytometer using forward 
scatter gating (for particle size) and fluorescence gating (GP1bβ+ par-
ticles) to specifically analyze platelets.
Immunohistochemistry and coimmunofluorescence. 5-μm frozen sec-
tions were fixed in acetone, endogenous peroxides were blocked with 
3% hydrogen peroxide in methanol, and nonspecific proteins were 
blocked with 4% fish gelatin in Tris-buffered saline for 20 minutes. 
Proliferation and apoptosis were assessed using anti-Ki67 antibody 
(catalog RB-90-43-P; Thermo Scientific) and anti–caspase-3 antibody 
(catalog CP229B; BioCare Medical). For double immunofluorescence, 
Dylight488-labeled antibody against the GP1bβ subunit of the murine 
platelet/megakaryocyte-specific GPIb-V-IX complex (catalog X488, 
Emfret) was used in combination with a directly labeled antibody for 
CD31 (catalog 553373, BD Pharmingen). Hoechst 33342 was used for 
nuclear counterstain. Slides were mounted using propyl gallate (Fisher 
Scientific) and glass cover slips. Further, rabbit polyclonal antibody 
or snap frozen for lysate preparation. Additionally, blood was col-
lected from the inferior vena cava for subsequent CBC analysis.
Intravital fixation. At the time of animal sacrifice, mice were 
anesthetized with isoflurane, an incision was made in the chest cav-
ity allowing visualization of the left heart, and a 21-gauge needle 
was used to slowly deliver PBS and 4% paraformaldehyde. In indi-
cated experiments, fixation was preceded by i.v. injection of Dex-
tran (Sigma-Aldrich) or Hypoxyprobe (Hypoxyprobe Inc.) in two 
mice of each group.
Isolation of immune cells from the spleen. Spleens were harvested 
from WT or Pf4-Cre+ Fakfl/fl mice, and splenocytes were released by 
crushing the spleen through a 40-μm filter using the black rubber end 
of a syringe. Cells were washed once with PBS, and cell suspension 
was blocked with Mouse BD Fc Block (catalog 553141, BD Biosciences) 
for 20 minutes on ice. After a washing step using PBS/1% BSA, cells 
were incubated with anti-mouse F4/80-PE (catalog 12-4801-80, ebio-
science), anti-mouse CD3e-PerCP-Cy5.5 (catalog 45-0031-82, ebio-
science), and anti-mouse CD19-PE-Cy7 (catalog 25-0193-81, ebiosci-
ence) and diluted 1:200 in PBS/1%BSA for 30 minutes at 4°C in the 
dark. After washing twice, cells were resuspended in PBS/1% BSA and 
transferred to FACS tubes. Cell sorting and collection was performed 
on a BD Influx cell sorter.
Chitosan nanoparticle preparation. Chitosan nanoparticles were 
designed as previously described (62). Before in vivo administration, 
preparation was hydrated with distilled water at room temperature at 
a concentration of 150 μg siRNA per kg per injection. 100 μl of siRNA 
solution was injected i.v. twice weekly.
Immunoblot analysis. Lysates from cultured cells were prepared 
using modified RIPA buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 
1% Triton, 0.5% deoxycholate) plus phosphatase and proteins inhibi-
tors. The protein concentrations were determined using a BCA Protein 
Assay Reagent Kit (Pierce Biotechnology). Lysates were loaded and 
separated on SDS-PAGE. Proteins were transferred to a nitrocellulose 
membrane by electrophoresis (Bio-Rad Laboratories). Membranes 
were blocked with either 5% BSA (for phosphorylated proteins) or 
5% anhydrous milk powder in Tris-buffered saline (for total proteins) 
for 1 hour and then incubated at 4°C overnight with primary antibody 
(pFAK 1:1,000 [catalog 13009, Cell Signaling], FAK 1:1,000 [catalog 
8556, Cell Signaling]). After washing with Tris-buffered saline with 
Tween 20, the membranes were incubated with HRP-conjugated 
secondary antibody for 1 hour at room temperature. β-Actin (ACTB, 
1:5,000, catalog A5316, Sigma-Aldrich) was used as a loading control. 
For evaluation of angiogenesis-related proteins in platelets, we used 
Mouse Angiogenesis Antibody Array (catalog ARY015, R&D Systems 
Inc.) according to the manufacturer’s instructions. 150 μg platelet pro-
tein lysate was used for each group.
qRT-PCR analysis. For mRNA quantification, total RNA was iso-
lated using the Direct-zol RNA MiniPrep Kit (Zymo Research Corp.) 
and cDNAs were synthesized using the Verso cDNA Kit (Thermo Sci-
entific) per the manufacturers’ instructions. Analysis of mRNA levels 
was performed on a Mx3005P qPCR system (Agilent Technologies). 
The primers used are as follows: 18S fwd: 5′-CGCCGCTAGAGGT-
GAAATTC-3′, 18S rev: 5′-TTGGCAAATGCTTTCGCTC-3′, FAK fwd: 
5′-CAATGCCTCCAAATTGTCCT-3′, and FAK rev: 5′-TCCATCCT-
CATCCGTTCTTC-3′.
In vitro proliferation and apoptosis assays. Fifty thousand cells were 
plated in 6-well plates. Media were changed to serum-free media for 
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tosan nanoparticles for in vivo studies. VAK and AKS supervised 
and designed the study and wrote the manuscript.
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against Desmin (catalog ab8592, Abcam) was used to stain pericytes, 
and rat monoclonal antibody against CD31 (catalog 53370, BD Pharm-
ingen) was used to visualize blood vessels. The number of vessels and 
pericyte-covered CD31+ vessels and Ki67 and caspase-3 positivity were 
quantified in 5 randomly selected fields at ×200 magnification. The 
number of extravasated platelets was determined by counting them in 
10 randomly selected fields at ×200 or ×400 magnification.
Transmission electron microscopy. Tumor samples were immersion 
fixed in 0.1 M sodium cacodylate buffer (pH 7.2) containing 2.5% glu-
taraldehyde for 2 hours at room temperature. The tissues were subse-
quently rinsed in buffer and then post-fixed in 0.1 M sodium cacody-
late buffer containing 1% osmium tetroxide for 1 hour in the dark. The 
samples were rinsed in distilled water and then dehydrated through 
an acetone series (30%, 50%, 70%, 90%, and 100% acetone) prior 
to embedding in Embed-812 epoxy resin (Electron Microscopy Sci-
ences). Ultrathin sections (100 nm) were post-stained with uranyl ace-
tate and lead citrate prior to imaging on a Tecnai G2 Spirit BioTWIN 
(FEI Company) transmission electron microscope.
ADP quantification. The relative levels of ADP in cell culture 
supernatants or tumor tissue lysates were evaluated using the ADP 
Colorimetric Assay Kit (Abcam) according to the manufacturer’s pro-
tocol. Supernatants of normoxic or hypoxic SKOV3ip1 cells from 3 dif-
ferent experiments were used. To quantify ADP levels in tumors, two 
in vivo samples of each group were used.
Statistics. Statistical analysis was performed using Excel and 
GraphPad Prism 6. Differences between groups were evaluated using 
2-tailed Student’s t test or 1-way ANOVA, adjusting for multiple com-
parisons. Results are presented as the mean ± SEM. For all statistical 
analyses, P < 0.05 was considered statistically significant.
Study approval. All approvals for experiments depicted here were 
obtained from The University of Texas MD Anderson Cancer Center 
Institutional Review Board. All animal experiments were approved 
and supervised by the MD Anderson Cancer Center Institutional Ani-
mal Care and Use Committee.
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